Literature DB >> 17616664

Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Laura Gramantieri1, Manuela Ferracin, Francesca Fornari, Angelo Veronese, Silvia Sabbioni, Chang-Gong Liu, George A Calin, Catia Giovannini, Eros Ferrazzi, Gian Luca Grazi, Carlo M Croce, Luigi Bolondi, Massimo Negrini.   

Abstract

We investigated the role of microRNAs (miRNAs) in the pathogenesis of human hepatocellular carcinoma (HCC). A genome-wide miRNA microarray was used to identify differentially expressed miRNAs in HCCs arisen on cirrhotic livers. Thirty-five miRNAs were identified. Several of these miRNAs were previously found deregulated in other human cancers, such as members of the let-7 family, mir-221, and mir-145. In addition, the hepato-specific miR-122a was found down-regulated in approximately 70% of HCCs and in all HCC-derived cell lines. Microarray data for let-7a, mir-221, and mir-122a were validated by Northern blot and real-time PCR analysis. Understanding the contribution of deregulated miRNAs to cancer requires the identification of gene targets. Here, we show that miR-122a can modulate cyclin G1 expression in HCC-derived cell lines and an inverse correlation between miR-122a and cyclin G1 expression exists in primary liver carcinomas. These results indicate that cyclin G1 is a target of miR-122a and expand our knowledge of the molecular alterations involved in HCC pathogenesis and of the role of miRNAs in human cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616664     DOI: 10.1158/0008-5472.CAN-06-4607

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  338 in total

1.  Negative feedback of miR-29 family TET1 involves in hepatocellular cancer.

Authors:  Li Li Lin; Wei Wang; ZhaoYang Hu; Li Wen Wang; Jing Chang; HanGuang Qian
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

2.  Environmental chemical exposures and human epigenetics.

Authors:  Lifang Hou; Xiao Zhang; Dong Wang; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2011-12-13       Impact factor: 7.196

Review 3.  MicroRNAs in liver disease.

Authors:  Xin Wei Wang; Niels H H Heegaard; Henrik Orum
Journal:  Gastroenterology       Date:  2012-04-11       Impact factor: 22.682

Review 4.  MicroRNA, nutrition, and cancer prevention.

Authors:  Sharon A Ross; Cindy D Davis
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

5.  Function and clinical potential of microRNAs in hepatocellular carcinoma.

Authors:  Lijuan Wang; Yongfang Yue; Xian Wang; Hongchuan Jin
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

Review 6.  Lin28 and let-7 in cell metabolism and cancer.

Authors:  Liem H Nguyen; Hao Zhu
Journal:  Transl Pediatr       Date:  2015-01

7.  Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies.

Authors:  Alessia Piluso; Laura Gragnani; Elisa Fognani; Elena Grandini; Monica Monti; Cristina Stasi; Elisabetta Loggi; Marzia Margotti; Fabio Conti; Pietro Andreone; Anna Linda Zignego
Journal:  Hepatol Int       Date:  2015-08-14       Impact factor: 6.047

8.  Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Giacomo Diaz; Marta Melis; Ashley Tice; David E Kleiner; Lopa Mishra; Fausto Zamboni; Patrizia Farci
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

9.  Non-inhibited miRNAs shape the cellular response to anti-miR.

Authors:  John R Androsavich; B Nelson Chau
Journal:  Nucleic Acids Res       Date:  2014-05-07       Impact factor: 16.971

10.  Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma.

Authors:  J Qi; J Wang; H Katayama; S Sen; S M Liu
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.